Praxis Q1 2026 Earnings Call Highlights FDA NDA Acceptance and Market Potential
During Praxis' (PRAX) first-quarter earnings call, management highlighted key developments including FDA acceptance of NDAs for ulixacaltamide and relutrigine. The company is preparing for a U.S. commercial launch of ulixacaltamide with an estimated peak sales potential exceeding $10 billion.
Tickers: $PRAX